aTyr Pharma develops biologic therapeutics based on Physiocrine biology. The Company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. The Company's key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development.
Type
Public
HQ
San Diego, US
Founded
2005
Size (employees)
58 (est)
aTyr Pharma was founded in 2005 and is headquartered in San Diego, US
Report incorrect company information

aTyr Pharma Office Locations

aTyr Pharma has an office in San Diego
San Diego, US (HQ)
3545 John Hopkins Ct
Show all (1)
Report incorrect company information

aTyr Pharma Financials and Metrics

aTyr Pharma Financials

USD

Net income (Q1, 2018)

(10.7 m)

EBIT (Q1, 2018)

(10.2 m)

Market capitalization (23-May-2018)

27.3 m

Closing share price (23-May-2018)

0.9

Cash (31-Mar-2018)

21.9 m
aTyr Pharma's current market capitalization is $27.3 m.
Annual
USDFY, 2015FY, 2016FY, 2017

General and administrative expense

13.1 m15.1 m17.1 m

R&D expense

34.5 m42.8 m30.1 m

Operating expense total

47.6 m57.9 m47.1 m

EBIT

(47.6 m)(57.9 m)(47.1 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

General and administrative expense

2.3 m3.4 m3.6 m4.1 m4.1 m3.5 m4 m3.5 m3.7 m4.1 m

R&D expense

6.6 m7.5 m7.7 m12 m11.3 m10.4 m9.2 m8.4 m7.1 m6.2 m

Operating expense total

8.9 m10.9 m11.3 m16.1 m15.4 m13.9 m13.2 m11.9 m10.8 m10.2 m

Depreciation and amortization

552 k
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

53 m38.4 m21.1 m

Current Assets

98 m74.8 m87 m

PP&E

1.8 m1.4 m2.3 m

Total Assets

129.7 m80.5 m89.4 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

54.5 m63.1 m60.1 m54.1 m43.2 m34.3 m28.9 m35.9 m29.8 m21.9 m

Current Assets

55.2 m106.2 m111.4 m87.6 m85.9 m73.6 m63.8 m59.1 m92.2 m76 m

PP&E

1.8 m2 m1.8 m1.8 m1.8 m1.6 m1.6 m2 m2.2 m2.4 m

Total Assets

59.9 m153.1 m141.4 m115.1 m100.5 m85.9 m65.7 m61.5 m94.5 m78.5 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(48 m)(57.9 m)(48.2 m)

Depreciation and Amortization

869 k900 k713 k

Accounts Payable

3.9 m(932 k)(2.5 m)

Cash From Operating Activities

(36.8 m)(52.9 m)(42.4 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(9.1 m)(11.1 m)(11.3 m)(16.1 m)(15.4 m)(13.8 m)(13.4 m)(10.7 m)

Depreciation and Amortization

184 k

Accounts Payable

3.2 m3 m1.6 m5.9 m4.7 m3.6 m1.2 m(999 k)

Cash From Operating Activities

(10.6 m)
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information